AnaptysBio Inc. Common Stock (ANAB)

FairStock Score: 53/100 — MIXED

Key Financials

Strengths

• Generates $8 million in annual free cash flow (0.6% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Superior net profit margin of 21.3% indicating pricing power and operational efficiency
• Revenue growth of 151.1% demonstrates strong top-line momentum

Concerns

• High leverage at 21.76x debt-to-equity increases financial risk and interest expense burden
• Altman Z-Score of 1.7 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

AnaptysBio Inc. Common Stock is a micro-cap healthcare company valued at $1.5 billion. The business generates $232 million in annual revenue with a 21.3% net margin and $8 million in free cash flow. From a quality standpoint, AnaptysBio shows solid Piotroski F-Score of 7/9 and distressed Altman Z-Score of 1.7 warrants caution. On valuation, the stock is solid 6.6% FCF yield. Growth dynamics show revenue growing at 151.1% and profit growth of 327.8%. Our composite FairStock Score of 53/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

AnaptysBio's 151% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $8 million in annual free cash flow (0.6% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Elevated leverage at 21.8x D/E means rising interest rates or revenue weakness could strain debt covenants and force asset sales at distressed prices. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer